Market Overview

Cellectis Reports 4th Quarter and Full Year 2018 Financial Results

Share:
  • UCART123 in Phase 1 dose escalation clinical trial ongoing for AML;
  • UCART22 received FDA and IRB approvals for Phase 1 dose escalation
    clinical trial in B-ALL patients;
  • UCART19 ASH abstract by partners Servier and Allogene showed continued
    progress of first clinical allogeneic CAR T-cell program for ALL adult
    and pediatric patients;
  • Cellectis, through its new subsidiary Cellectis Biologics, Inc.,
    entered into a lease agreement to build a manufacturing facility in
    North Carolina, advancing commercialization capabilities for its UCART
    portfolio
  • Cash position1 of $452M as of December 31, 2018 compared to
    $297M as of December 31, 2017

Regulatory News:

Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS -
Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on
developing immunotherapies based on gene-edited allogeneic CAR T-cells
(UCART), today announced its results for the fourth quarter 2018 and
full year ended December 31, 2018.

 

Earnings Call Details

 
Cellectis to hold a conference call for investors on March 12, 2019
at 7:30 a.m. EDT – 12:30 p.m. Central European Time (CET). The call
will include the Company's fourth quarter 2018 and year-end
financial results.
 
The live dial-in information for the conference call is:
US & Canada only: 877-407-3104
International: 201-493-6792
In addition, a replay of the call will be available for 6 months
following the conference by calling 877-660-6853 (Toll Free US &
Canada); 201-612-7415 (Toll Free International).

1 Cash position includes cash, cash equivalents and current
financial assets

Fourth Quarter 2018 and Recent Highlights

Proprietary Development Programs

  • GMP Manufacturing

Over the course of 2018, we have conducted GMP manufacturing runs for
two of our leading proprietary development programs UCART123 and
UCART22. Manufacturing is currently performed at two contract
manufacturing organizations, MolMed and CellForCure.

We have initiated the establishment of a 14,000 square foot in-house
manufacturing facility in Paris, France called the SMART facility, which
stands for "Starting MAterial Realization for CAR-T products". This
facility is designed to supply our raw material for our clinical
studies. Internalizing this supply would significantly reduce our
manufacturing cycle time and improve our flexibility during clinical
development of our product candidates. This facility is planned to
go-live in 2020. We also anticipate that the SMART facility will have
the potential to supply commercial starting material for our CAR T-cell
products following potential FDA approval.

In March 2019, we entered into a lease agreement for an 82,000 square
foot commercial-scale manufacturing facility, called the IMPACT site,
which stands for "Innovative Manufacturing Plant for Allogeneic Cellular
Therapies". The IMPACT facility is located in Raleigh, North Carolina.
The new manufacturing facility is being designed to provide GMP
manufacturing for clinical supply and commercial production upon
potential regulatory approval. The facility is planned to be operational
by 2021.

  • UCART123 in AML patients

The Phase 1 dose escalation clinical studies for UCART123 in acute
myeloid leukemia (AML) patients at MD Anderson Cancer Center and Weill
Cornell Medical Center remains ongoing. In August 2018, we entered into
new clinical study agreements with Dana Farber Cancer Institute and H.
Lee Moffitt Cancer Center in order to expand the performance of the
UCART123 clinical study in AML to these sites.

For the AML clinical trial, the current dose level of 2.5x105
UCART123 cells per kilogram will be followed by dose levels 2 and 3 with
6.25x105 and 5.05x106 UCART123 cells per kilogram.
We are expecting to dose 2-4 patients per dose cohort, with a treatment
follow-up period of 4 weeks per patient as well as an option to re-dose
responding patients.

  • UCART22 in B-ALL patients

The FDA approved our IND for the UCART22 Phase 1 clinical study which is
designed to assess the safety and tolerability at increasing dose levels
in B-cell acute lymphoblastic leukemia (B-ALL) adult patients.

UCART22 is designed for the treatment of CD22-expressing cancer cells.
Like CD19, CD22 is a cell surface antigen expressed from the pre-B-cell
stage of development through mature B-cells and is expressed in more
than 90% of patients with B-ALL. Approximately 85% of ALL cases involve
precursor B-cells (B-ALL). The clinical study for UCART22 will be led by
Dr. Nitin Jain, Assistant Professor at The University of Texas MD
Anderson Cancer Center in Houston, and Dr. Hagop Kantarjian, Professor
and Chair in the Department of Leukemia and University Chair in Cancer
Medicine at The University of Texas MD Anderson Cancer Center in Houston.

  • UCARTCS1 in Multiple Myeloma patients

We have chosen CS1 (also known as SLAMF7) as the targeted antigen for
multiple myeloma (MM), based on the high levels of expression of CS1 in
MM patients on malignant cells relative to the low level of expression
on non-malignant cells as well as on the results of third parties' proof
of concept for this high value target achieved with the elotuzumab
monoclonal antibody in MM patients. We expect to start a clinical study
with UCARTCS1 in 2019.

  • UCART19 (exclusively licensed to Servier, and under collaboration
    between Servier and Allogene) in ALL adult and pediatric patients

At the 60th American Society of Hematology (ASH) Annual
Meeting, our partners Servier and Allogene presented updated data on
UCART19, showing the continued progress of UCART19 Phase 1 clinical
trials for both pediatric and adult ALL patients.

After UCART19 infusion, 82% (14/17) of patients who received a
lymphodepletion regimen (consisting of fludarabine, cyclophosphamide and
alemtuzumab, an anti-CD52 monoclonal antibody) achieved complete
remission, or "CR", or complete remission with incomplete blood cell
recovery (or "Cri") by day 28 or day 42 after infusion. Within responder
patients, 71% (10/14) of them were ‘minimum residual disease' (MRD)
negative (MRD- stands for less than 1 leukemic cell among 10E4 normal
cells) assessed by flow or qPCR. When considering all treated patients,
67% (14/21) of them did achieve CR/CRi. Regarding safety considerations,
there was no serious adverse events (grade ≥3) for graft versus host
disease (GvHD) and neurological events. Grade 3-4 toxicities did only
regard events of cytokine release syndrome (14%, 3/21), prolonged
cytopenia (29%, 6/21) and viral infections (24%, 5/21).

We are pleased to see continued progress for UCART19 under the direction
of our partners Servier and Allogene. Under our license, development and
commercialization agreement with Servier, Cellectis is entitled to
receive clinical and commercial milestone payments as well as tiered
royalties in the high single digits on worldwide sales.

  • ALLO-715 (BCMA) and ALLO-819 (Flt3) (exclusively licensed to
    Allogene Therapeutic, Inc.)

In addition, Allogene presented at ASH 2018 pre-clinical research on
ALLO-715, an allogeneic BCMA CAR T therapy possessing an off-switch for
the treatment of Multiple Myeloma, and a poster presentation for
ALLO-819, an allogeneic Flt3 CAR T therapy possessing an off-switch for
the treatment of acute myeloid leukemia (AML).

ALLO-715 and ALLO-819 were progressed under a joint research
collaboration between Allogene and Cellectis, and are directed to
targets that are licensed exclusively from Cellectis. Allogene holds the
exclusive global development and commercial rights for these product
candidates.

Pursuant to our license agreement with Allogene, we are entitled to
receive development and sales milestone payments of up to $2.8 billion,
or $185 million per target for 15 targets. We are eligible to receive
tiered royalties in the high single digits on worldwide sales of any
products that are developed by Allogene.

Corporate

On March 13, 2018, Elsy Boglioli was named Chief Operating Officer, to
succeed to Dr. Mathieu Simon who retired. Dr. Mathieu Simon also
resigned from his board member position.

On September 19, 2018, Stephan A. Grupp, MD, Ph.D., a leading pediatric
oncologist at Children's Hospital of Philadelphia and Chief of the
Section of Cellular Therapy and Transplant at the Children's Hospital of
Philadelphia (CHOP) joined the Company's Clinical Advisory Board.

On December 10, 2018, Bill Monteith was appointed to the role of Senior
Vice President U.S. Manufacturing. This appointment followed Cellectis'
plan to establish commercial manufacturing capabilities in the U.S.,
which is Bill Monteith's responsibility, notably through the deployment
of IMPACT. Bill Monteith joined Cellectis from Hitachi Chemical Advanced
Therapeutics Solutions, where he was the Chief Operating Officer and
Site General Manager for three manufacturing facilities.

Financial Results

The consolidated financial statements of Cellectis and Calyxt, of which
Cellectis is a 69.5% shareholder, have been prepared in accordance with
International Financial Reporting Standards, or IFRS, as issued by the
International Accounting Standards Board ("GAAP").

The breakdown of these consolidated financials between Cellectis and
Calyxt is in the appendices of this Q4 2018 financial results press
release.

Fourth Quarter and Full year 2018 Financial Results

Cash: As of December 31, 2018, Cellectis and Calyxt together had
$452 million in consolidated cash, cash equivalents, current financial
assets, of which $358 million was attributable to Cellectis. This
compares to $297 million in consolidated cash as of December 31, 2017,
of which $240 million was attributable to Cellectis. This net increase
of $155 million primarily reflects $227 million in net cash proceeds
provided by two separate follow-on offerings completed by Cellectis and
Calyxt in 2018. Net cash flows used by operating activities in 2018 were
$68 million, of which $48 million attributable to Cellectis. We believe
that the consolidated cash, cash equivalents and current financial
assets attributed as of December 31, 2018 will be sufficient to fund
operations through 2021.

Revenues and Other Income: Consolidated revenues and other income
were $3 million for the three months ended December 31, 2018 compared to
$7 million for the three months ended December 31, 2017. Consolidated
revenues and other income were $21 million for the year ended December
31, 2018 compared to $34 million for the year ended December 31, 2017.
98% of consolidated revenues and other income was attributed to
Cellectis in 2018. This decrease between 2018 and 2017 was mainly
attributable to a decrease in recognition of upfront payments already
received and R&D cost reimbursements in relation to the therapeutic
collaborations.

R&D Expenses: Consolidated R&D expenses remained stable $21
million for the three months ended December 31, 2018 and 2017.
Consolidated R&D expenses were $77 million for the year ended December
31, 2018 compared to $79 million for the year ended December 31, 2017.
89% of consolidated R&D expenses was attributed to Cellectis in 2018.
The $2 million decrease between 2018 and 2017 was primarily attributed
to the reduction of non-cash stock-based compensation expenses by $6
million and social charges on stock option grants by $1 million. This
decrease was partially offset by higher employee expenses by $4 million,
notably due to more R&D headcount, and higher purchases and external and
other expenses by $1 million.

SG&A Expenses: Consolidated SG&A expenses were $11 million
for the three months ended December 31, 2018 compared to $13 million for
the three months ended December 31, 2017. The decrease was primarily
attributable to decreased non-cash stock-based compensation expenses and
social charges on stock option grants. Consolidated SG&A expenses were
$47 million for the year ended December 31, 2018 compared to $45 million
for the year ended December 31, 2017. 55% of consolidated SG&A expenses
was attributed to Cellectis in 2018. The $2 million increase between
2018 and 2017 was primarily driven by the increase in wages and
purchases at Calyxt of $8 million in relation to the ramp-up of its
commercialization capabilities and to its expenses associated with being
a public company. This increase was partially offset by lower non-cash
stock-based compensation of $7 million.

Net Loss Attributable to Shareholders of Cellectis: The
consolidated Net loss attributable to Shareholders of Cellectis was $23
million (or $0.53 per share) for the three months ended December 31,
2018 compared to $27 million (or $0.76 per share) for the three months
ended December 31, 2017. The consolidated Net loss attributable to
Shareholders of Cellectis was $79 million (or $1.93 per share) for the
year ended December 31, 2018, of which $60 million was attributed to
Cellectis, compared to $99 million (or $2.78 per share) for the year
ended December 31, 2017, of which $85 million was attributed to
Cellectis. This $20 million decrease in net loss between 2018 and 2017
was primarily driven by a significant increase in net financial gains of
$28 million and partially offset by an increase in operating losses of
$12 million, of which $11 million was attributed to Calyxt.

Adjusted Net Loss Attributable to Shareholders of Cellectis: The
consolidated Adjusted net loss attributable to Shareholders of
Cellectis was $16 million (or $0.37 per share) for the three months
ended December 31, 2018 compared to $16 million (or $0.46 per share) for
the three months ended December 31, 2017. The consolidated adjusted net
loss attributable to Shareholders of Cellectis, which excludes the
non-cash stock-based compensation expenses, was $44 million (or $1.08
per share) for the year ended December 31, 2018, of which $31 million is
attributed to Cellectis, compared to $50 million (or $1.41 per share)
for the year ended December 31, 2017, of which $42 million was
attributed to Cellectis. Please see "Note Regarding Use of Non-GAAP
Financial Measures" for reconciliation of GAAP net income (loss)
attributable to shareholders of Cellectis to adjusted net income (loss)
attributable to shareholders of Cellectis.

We foresee focusing on our cash spending on Cellectis for 2019 in the
following areas:

  • Supporting our rich product candidates pipeline including
    manufacturing and clinical trials expenses of UCART123, UCART22 and
    UCARTCS1,
  • Building state-of-the-art manufacturing capabilities, and
  • Strengthening our manufacturing and clinical departments, including
    hiring talented personnel.

Calyxt plans to focus its cash spending for 2019 in the following areas:

  • Launching their High-Oleic Soybean products, including their Calyno™
    High-Oleic Soybean Oil and Soybean Meal,
  • Supporting its rich innovative product pipeline, and
  • Strengthening its commercial and general and administration support.

CELLECTIS S.A.

STATEMENT OF CONSOLIDATED FINANCIAL POSITION

($ in thousands)

 
As of
December 31, 2017 as restated (*)   December 31, 2018
 
ASSETS
Non-current assets
Intangible assets 1 431 1 268
Property, plant, and equipment 7 226 10 041
Other non-current financial assets 1 004 1 891
Total non-current assets 9 661 13 199
 
Current assets
Inventories 250 275
Trade receivables 2 753 2 971
Subsidies receivables 9 524 17 173
Other current assets 13 713 15 333
Cash and cash equivalent and Current financial assets 296 982 451 889
Total current assets 323 221 487 641
TOTAL ASSETS 332 882 500 840
 
LIABILITIES
Shareholders' equity
Share capital 2 367 2 765
Premiums related to the share capital 614 037 828 525
Treasury share reserve (297) 0
Currency translation adjustment 1 834 (16 668)
Retained earnings (253 702) (326 628)
Net income (loss) (99 368) (78 693)
Total shareholders' equity - Group Share 264 872 409 301
Non-controlling interests 19 113 40 970
Total shareholders' equity 283 985 450 272
 
Non-current liabilities
Non-current financial liabilities 13 1 018
Non-current provisions 3 430 2 681
Total non-current liabilities 3 443 3 699
 
Current liabilities
Current financial liabilities 21 333
Trade payables 9 460 15 883
Deferred revenues and deferred income 27 975 20 754
Current provisions 1 427 1 530
Other current liabilities 6 570 8 369
Total current liabilities 45 453 46 869
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 332 882 500 840

(*) 2018 consolidated financial statements have been restated for the
purpose of IFRS15 application. Reconciliation between interim
consolidated financial statements presented in previous periods and 2018
consolidated financial statements is available in Note 2.3 of the
consolidated financial statements, available in our annual report on
Form 20-F for the year ended December 31, 2018.

CELLECTIS S.A.

STATEMENT OF CONSOLIDATED OPERATIONS – Fourth quarter

(unaudited)

($ in thousands, except per share data)

 
For the three-month periods ended December 31,
2017   2018
 
Revenues and other income
Revenues 5 725 968
Other income 1 185 2 108
Total revenues and other income 6 910 3 077
Operating expenses
Royalty expenses (883) (720)
Research and development expenses (20 704) (21 266)
Selling, general and administrative expenses (12 992) (10 517)
Other operating income (expenses) (94) 162
Total operating expenses (34 672) (32 341)
   
Operating income (loss) (27 762) (29 265)
   
Financial gain (loss) (958) 3 200
   
Net income (loss) (28 721) (26 065)
Attributable to shareholders of Cellectis (27 171) (23 075)
Attributable to non-controlling interests (1 550) (2 990)
   
Basic net income (loss) attributable to shareholders of Cellectis
per share ($/share)
(0,76) (0,53)
   
Diluted net income (loss) attributable to shareholders of
Cellectis per share ($/share)
(0,76) (0,53)

CELLECTIS S.A.

STATEMENT OF CONSOLIDATED
OPERATIONS – Full year

($ in thousands, except per share data)

 
For the years ended December 31,
2017   2018
 
Revenues and other income
Revenues 25 188 12 731
Other income 8 528 8 701
Total revenues and other income 33 715 21 432
Operating expenses
Royalty expenses (2 620) (2 739)
Research and development expenses (79 227) (76 567)
Selling, general and administrative expenses (44 750) (47 248)
Other operating income (expenses) 232 31
Total operating expenses (126 366) (126 523)
   
Operating income (loss) (92 650) (105 091)
   
Financial gain (loss) (11 032) 16 758
   
Net income (loss) (103 683) (88 333)
Attributable to shareholders of Cellectis (99 368) (78 693)
Attributable to non-controlling interests (4 315) (9 640)
   
Basic net income (loss) attributable to shareholders of Cellectis
per share ($/share)
(2,78) (1,93)
   
Diluted net income (loss) attributable to shareholders of
Cellectis per share ($/share)
(2,78) (1,93)

CELLECTIS S.A.

DETAILS OF KEY PERFORMANCE
INDICATORS BY REPORTABLE SEGMENTS – Fourth Quarter

(unaudited) - ($ in thousands)

   
For the quarter ended December 31, 2017 For the quarter ended December 31, 2018
Plants   Therapeutics   Total reportable segments Plants   Therapeutics   Total reportable segments
       
External revenues 190 5 535 5 725 4 964   968
External other income 50   1 135   1 185 172   1 937   2 108
External revenues and other income 240   6 670   6 910 176   2 901   3 077
Royalty expenses (348) (535) (883) (240) (481) (720)
Research and development expenses (1 856) (18 848) (20 704) (2 725) (18 541) (21 266)
Selling, general and administrative expenses (4 969) (8 023) (12 992) (6 436) (4 081) (10 517)
Other operating income and expenses 35   (129)   (94) (68)   230   162
Total operating expenses (7 138)   (27 534)   (34 672) (9 469)   (22 873)   (32 341)
Operating income (loss) before tax (6 898)   (20 865)   (27 762) (9 293)   (19 971)   (29 265)
Financial gain (loss) 139   (1 096)   (958) 418   2 782   3 200
Net income (loss) (6 759)   (21 962)   (28 721) (8 875)   (17 189)   (26 065)
Non controlling interests 1 550   -   1 550 2 990   -   2 990
Net income (loss) attributable to shareholders of Cellectis (5 209)   (21 962)   (27 171) (5 886)   (17 189)   (23 075)
R&D non-cash stock-based expense attributable to shareholder of
Cellectis
570 4 196 4 766 153 4 388 4 541
SG&A non-cash stock-based expense attributable to shareholder of
Cellectis
1 732   4 299   6 031 1 767   911   2 678
Adjustment of share-based compensation attributable to
shareholders of Cellectis
2 302   8 494   10 796 1 920   5 299   7 219
Adjusted net income (loss) attributable to shareholders of
Cellectis
(2 907)   (13 468)   (16 374) (3 966)   (11 890)   (15 856)
                   
Net cash used in operating activities (6 817)   (2 696)   (9 513) (6 652)   (13 950)   (20 602)

CELLECTIS S.A.

DETAILS OF KEY PERFORMANCE
INDICATORS BY REPORTABLE SEGMENTS – Full Year

($ in thousands)

   
For the year ended December 31, 2017 For the year ended December 31, 2018
Plants   Therapeutics   Total reportable segments Plants   Therapeutics   Total reportable segments
       
External revenues 508 24 680 25 188 236 12 495   12 731
External other income 239   8 290   8 528 178   8 523   8 701
External revenues and other income 747   32 969   33 715 414   21 018   21 432
Royalty expenses (390) (2 230) (2 620) (595) (2 144) (2 739)
Research and development expenses (6 057) (73 170) (79 227) (8 638) (67 929) (76 567)
Selling, general and administrative expenses (13 143) (31 607) (44 750) (21 067) (26 180) (47 248)
Other operating income and expenses 6   225   232 (50)   81   31
Total operating expenses (19 584)   (106 782)   (126 366) (30 351)   (96 172)   (126 523)
Operating income (loss) before tax (18 837)   (73 813)   (92 650) (29 937)   (75 154)   (105 091)
Financial gain (loss) 0   (11 032)   (11 032) 1 420   15 339   16 758
Net income (loss) (18 837)   (84 846)   (103 683) (28 517)   (59 816)   (88 333)
Non controlling interests 4 315   -   4 315 9 640   -   9 640
Net income (loss) attributable to shareholders of Cellectis (14 522)   (84 846)   (99 368) (18 877)   (59 816)   (78 693)
R&D non-cash stock-based expense attributable to shareholder of
Cellectis
967 22 623 23 590 838 16 852 17 689
SG&A non-cash stock-based expense attributable to shareholder of
Cellectis
4 990   20 345   25 335 5 218   11 655   16 873
Adjustment of share-based compensation attributable to
shareholders of Cellectis
5 957   42 968   48 925 6 056   28 507   34 563
Adjusted net income (loss) attributable to shareholders of
Cellectis
(8 565)   (41 877)   (50 443) (12 821)   (31 309)   (44 130)
                   
Net cash used in operating activities (12 785)   (39 542)   (52 327) (20 252)   (47 885)   (68 137)

Note Regarding Use of Non-GAAP Financial Measures

Cellectis S.A. presents adjusted net income (loss) attributable to
shareholders of Cellectis in this press release. Adjusted net income
(loss) attributable to shareholders of Cellectis is not a measure
calculated in accordance with IFRS. We have included in this press
release a reconciliation of this figure to net income (loss)
attributable to shareholders of Cellectis, which is the most directly
comparable financial measure calculated in accordance with IFRS. Because
adjusted net income (loss) attributable to shareholders of Cellectis
excludes non-cash stock-based compensation expense—a non-cash expense,
we believe that this financial measure, when considered together with
our IFRS financial statements, can enhance an overall understanding of
Cellectis' financial performance. Moreover, our management views
Cellectis' operations, and manages its business, based, in part, on this
financial measure. In particular, we believe that the elimination of
non-cash stock-based expenses from net income (loss) attributable to
shareholders of Cellectis can provide a useful measure for
period-to-period comparisons of our core businesses. Our use of adjusted
net income (loss) attributable to shareholders of Cellectis has
limitations as an analytical tool, and you should not consider it in
isolation or as a substitute for analysis of our financial results as
reported under IFRS. Some of these limitations are: (a) other companies,
including companies in our industry which use similar stock-based
compensation, may address the impact of non-cash stock-based
compensation expense differently; and (b) other companies may report
adjusted net income (loss) attributable to shareholders or similarly
titled measures but calculate them differently, which reduces their
usefulness as a comparative measure. Because of these and other
limitations, you should consider adjusted net income (loss) attributable
to shareholders of Cellectis alongside our IFRS financial results,
including net income (loss) attributable to shareholders of Cellectis.

RECONCILIATION OF GAAP TO NON-GAAP NET INCOME – Fourth quarter

(unaudited)

($ in thousands, except per share data)

 
For the three-month periods ended December 31,
2017   2018
 
Net income (loss) attributable to shareholders of Cellectis (27 171) (23 075)
Adjustment:
Non-cash stock-based compensation expense
attributable to shareholders of Cellectis
10 796 7 219
Adjusted net income (loss) attributable to shareholders of
Cellectis
(16 374) (15 856)
   
Basic Adjusted net income (loss) attributable to shareholders of
Cellectis ($/share)
(0,46) (0,37)
   
Weighted average number of outstanding shares, basic (units) (1) 35 949 421 42 430 040
   
Diluted Adjusted net income (loss) attributable to shareholders
of Cellectis ($/share) (1)
(0,46) (0,37)
   
Weighted average number of outstanding shares, diluted (units) (1) 36 128 350 42 560 947

(1) When we have adjusted net loss, in accordance with IFRS, we use the
Weighted average number of outstanding shares, basic to compute the
Diluted adjusted net income (loss) attributable to shareholders of
Cellectis ($/share). When we have adjusted net income, in accordance
with IFRS, we use the Weighted average number of outstanding shares,
diluted to compute the Diluted adjusted net income (loss) attributable
to shareholders of Cellectis ($/share)

RECONCILIATION OF GAAP TO NON-GAAP NET INCOME – Full Year

(unaudited)

($ in thousands, except per share data)

 
For the years ended December 31,
2017   2018
 
Net income (loss) attributable to shareholders of Cellectis (99 368) (78 693)
Adjustment:
Non-cash stock-based compensation expense
attributable to shareholders of Cellectis
48 925 34 563
Adjusted net income (loss) attributable to shareholders of
Cellectis
(50 443) (44 130)
   
Basic Adjusted net income (loss) attributable to shareholders of
Cellectis ($/share)
(1,41) (1,08)
   
Weighted average number of outstanding shares, basic (units) (1) 35 690 636 40 774 197
   
Diluted Adjusted net income (loss) attributable to shareholders
of Cellectis ($/share) (1)
(1,41) (1,08)
   
Weighted average number of outstanding shares, diluted (units) (1) 35 715 321 41 285 578

When we have adjusted net loss, in accordance with IFRS, we use the
Weighted average number of outstanding shares, basic to compute the
Diluted adjusted net income (loss) attributable to shareholders of
Cellectis ($/share). When we have adjusted net income, in accordance
with IFRS, we use the Weighted average number of outstanding shares,
diluted to compute the Diluted adjusted net income (loss) attributable
to shareholders of Cellectis ($/share).

About Cellectis

Cellectis is a clinical-stage biopharmaceutical company focused on
developing a new generation of cancer immunotherapies based on
gene-edited T-cells (UCART). By capitalizing on its 19 years of
expertise in gene editing – built on its flagship TALEN® technology and
pioneering electroporation system PulseAgile – Cellectis uses the power
of the immune system to target and eradicate cancer cells.

Using its life-science-focused, pioneering genome engineering
technologies, Cellectis' goal is to create innovative products in
multiple fields and with various target markets.

Cellectis is listed on the Nasdaq Global Market (NASDAQ:CLLS) and on
Euronext Growth (TICKER:ALCLS). To find out more about us, visit our
website: www.cellectis.com

Talking about gene editing? We do it. TALEN® is a registered trademark
owned by Cellectis.

Special Note Regarding Forward-Looking Statements

This press release contains "forward-looking" statements that are based
on our management's current expectations and assumptions and on
information currently available to management. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements.
Further information on the risk factors that may affect company business
and financial performance is included in Cellectis' Annual Report on
Form 20-F for the year ended December 31, 2018. Except as required by
law, we assume no obligation to update these forward-looking statements
publicly, or to update the reasons actual results could differ
materially from those anticipated in the forward-looking statements,
even if new information becomes available in the future.

###

View Comments and Join the Discussion!